Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience

S Massironi, Davide Campana, S Partelli, F Panzuto, RE Rossi, A Faggiano, Nicole Brighi, M Falconi, M Rinzivillo, Gianfranco Delle Fave, AM Colao, D Conte

Research output: Contribution to journalArticle

Abstract

Background: The optimal management of duodenal neuroendocrine neoplasms (dNENs) is unclear, and endoscopic resection is increasingly performed instead of surgery. Methods: This is a retrospective analysis of patients with histologically confirmed diagnosis of dNENs, managed at five Italian tertiary referral Centers in Italy. Results: From 2000 to 2017, 108 patients (69 males, 39 females, median age 59.5 years) were included in this study. Seventy-one patients had G1, 21 G2, 4 G3 dNENs (12 Ki-67 not available). Fifty-four patients showed metastases at diagnosis, and 20 patients developed metachronous metastases. Thirty patients had a functioning dNEN (14 metastatic). Fifty-seven patients had the dNEN surgically resected, 16 endoscopically, 23 metastatic, received medical therapy + surgery or endoscopy. Seven patients underwent liver-directed therapies, and one patient had PRRT. Median OS was 187 months. During a median follow-up of 76 months, 20 patients died (19 of disease-related causes). At Cox’s multivariate proportional hazard regression, grading and age were the only variables independently related to OS. Median PFS was 170 months. Grading and staging at the initial diagnosis were independently related to PFS. No differences in terms of OS and PFS were observed between patients treated surgically or endoscopically. Conclusions: dNENs prognosis may be highly variable. These tumors can be metastatic in up to 50% of cases at the time of first diagnosis and can develop metastases thereafter. Functioning neoplasms express high metastatic potential. Nuclear imaging should be performed to exclude distant metastases in all dNENs. Endoscopy and surgery play a primary role in the management of the disease. Further prospective studies are needed. © 2018, Society of Surgical Oncology.
Original languageEnglish
Pages (from-to)3200-3206
Number of pages7
JournalAnnals of Surgical Oncology
Volume25
Issue number11
DOIs
Publication statusPublished - 2018

Fingerprint

Neuroendocrine Tumors
Duodenal Neoplasms
Neoplasm Metastasis
Endoscopy
Disease Management
Tertiary Care Centers
Italy
Neoplasms
Prospective Studies

Cite this

Massironi, S., Campana, D., Partelli, S., Panzuto, F., Rossi, RE., Faggiano, A., ... Conte, D. (2018). Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. Annals of Surgical Oncology, 25(11), 3200-3206. https://doi.org/10.1245/s10434-018-6673-5

Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. / Massironi, S; Campana, Davide; Partelli, S; Panzuto, F; Rossi, RE; Faggiano, A; Brighi, Nicole; Falconi, M; Rinzivillo, M; Delle Fave, Gianfranco; Colao, AM; Conte, D.

In: Annals of Surgical Oncology, Vol. 25, No. 11, 2018, p. 3200-3206.

Research output: Contribution to journalArticle

Massironi, S, Campana, D, Partelli, S, Panzuto, F, Rossi, RE, Faggiano, A, Brighi, N, Falconi, M, Rinzivillo, M, Delle Fave, G, Colao, AM & Conte, D 2018, 'Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience', Annals of Surgical Oncology, vol. 25, no. 11, pp. 3200-3206. https://doi.org/10.1245/s10434-018-6673-5
Massironi, S ; Campana, Davide ; Partelli, S ; Panzuto, F ; Rossi, RE ; Faggiano, A ; Brighi, Nicole ; Falconi, M ; Rinzivillo, M ; Delle Fave, Gianfranco ; Colao, AM ; Conte, D. / Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. In: Annals of Surgical Oncology. 2018 ; Vol. 25, No. 11. pp. 3200-3206.
@article{154d630749fd48899a14edd09e89569a,
title = "Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience",
abstract = "Background: The optimal management of duodenal neuroendocrine neoplasms (dNENs) is unclear, and endoscopic resection is increasingly performed instead of surgery. Methods: This is a retrospective analysis of patients with histologically confirmed diagnosis of dNENs, managed at five Italian tertiary referral Centers in Italy. Results: From 2000 to 2017, 108 patients (69 males, 39 females, median age 59.5 years) were included in this study. Seventy-one patients had G1, 21 G2, 4 G3 dNENs (12 Ki-67 not available). Fifty-four patients showed metastases at diagnosis, and 20 patients developed metachronous metastases. Thirty patients had a functioning dNEN (14 metastatic). Fifty-seven patients had the dNEN surgically resected, 16 endoscopically, 23 metastatic, received medical therapy + surgery or endoscopy. Seven patients underwent liver-directed therapies, and one patient had PRRT. Median OS was 187 months. During a median follow-up of 76 months, 20 patients died (19 of disease-related causes). At Cox’s multivariate proportional hazard regression, grading and age were the only variables independently related to OS. Median PFS was 170 months. Grading and staging at the initial diagnosis were independently related to PFS. No differences in terms of OS and PFS were observed between patients treated surgically or endoscopically. Conclusions: dNENs prognosis may be highly variable. These tumors can be metastatic in up to 50{\%} of cases at the time of first diagnosis and can develop metastases thereafter. Functioning neoplasms express high metastatic potential. Nuclear imaging should be performed to exclude distant metastases in all dNENs. Endoscopy and surgery play a primary role in the management of the disease. Further prospective studies are needed. {\circledC} 2018, Society of Surgical Oncology.",
author = "S Massironi and Davide Campana and S Partelli and F Panzuto and RE Rossi and A Faggiano and Nicole Brighi and M Falconi and M Rinzivillo and {Delle Fave}, Gianfranco and AM Colao and D Conte",
year = "2018",
doi = "10.1245/s10434-018-6673-5",
language = "English",
volume = "25",
pages = "3200--3206",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York LLC",
number = "11",

}

TY - JOUR

T1 - Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience

AU - Massironi, S

AU - Campana, Davide

AU - Partelli, S

AU - Panzuto, F

AU - Rossi, RE

AU - Faggiano, A

AU - Brighi, Nicole

AU - Falconi, M

AU - Rinzivillo, M

AU - Delle Fave, Gianfranco

AU - Colao, AM

AU - Conte, D

PY - 2018

Y1 - 2018

N2 - Background: The optimal management of duodenal neuroendocrine neoplasms (dNENs) is unclear, and endoscopic resection is increasingly performed instead of surgery. Methods: This is a retrospective analysis of patients with histologically confirmed diagnosis of dNENs, managed at five Italian tertiary referral Centers in Italy. Results: From 2000 to 2017, 108 patients (69 males, 39 females, median age 59.5 years) were included in this study. Seventy-one patients had G1, 21 G2, 4 G3 dNENs (12 Ki-67 not available). Fifty-four patients showed metastases at diagnosis, and 20 patients developed metachronous metastases. Thirty patients had a functioning dNEN (14 metastatic). Fifty-seven patients had the dNEN surgically resected, 16 endoscopically, 23 metastatic, received medical therapy + surgery or endoscopy. Seven patients underwent liver-directed therapies, and one patient had PRRT. Median OS was 187 months. During a median follow-up of 76 months, 20 patients died (19 of disease-related causes). At Cox’s multivariate proportional hazard regression, grading and age were the only variables independently related to OS. Median PFS was 170 months. Grading and staging at the initial diagnosis were independently related to PFS. No differences in terms of OS and PFS were observed between patients treated surgically or endoscopically. Conclusions: dNENs prognosis may be highly variable. These tumors can be metastatic in up to 50% of cases at the time of first diagnosis and can develop metastases thereafter. Functioning neoplasms express high metastatic potential. Nuclear imaging should be performed to exclude distant metastases in all dNENs. Endoscopy and surgery play a primary role in the management of the disease. Further prospective studies are needed. © 2018, Society of Surgical Oncology.

AB - Background: The optimal management of duodenal neuroendocrine neoplasms (dNENs) is unclear, and endoscopic resection is increasingly performed instead of surgery. Methods: This is a retrospective analysis of patients with histologically confirmed diagnosis of dNENs, managed at five Italian tertiary referral Centers in Italy. Results: From 2000 to 2017, 108 patients (69 males, 39 females, median age 59.5 years) were included in this study. Seventy-one patients had G1, 21 G2, 4 G3 dNENs (12 Ki-67 not available). Fifty-four patients showed metastases at diagnosis, and 20 patients developed metachronous metastases. Thirty patients had a functioning dNEN (14 metastatic). Fifty-seven patients had the dNEN surgically resected, 16 endoscopically, 23 metastatic, received medical therapy + surgery or endoscopy. Seven patients underwent liver-directed therapies, and one patient had PRRT. Median OS was 187 months. During a median follow-up of 76 months, 20 patients died (19 of disease-related causes). At Cox’s multivariate proportional hazard regression, grading and age were the only variables independently related to OS. Median PFS was 170 months. Grading and staging at the initial diagnosis were independently related to PFS. No differences in terms of OS and PFS were observed between patients treated surgically or endoscopically. Conclusions: dNENs prognosis may be highly variable. These tumors can be metastatic in up to 50% of cases at the time of first diagnosis and can develop metastases thereafter. Functioning neoplasms express high metastatic potential. Nuclear imaging should be performed to exclude distant metastases in all dNENs. Endoscopy and surgery play a primary role in the management of the disease. Further prospective studies are needed. © 2018, Society of Surgical Oncology.

U2 - 10.1245/s10434-018-6673-5

DO - 10.1245/s10434-018-6673-5

M3 - Article

VL - 25

SP - 3200

EP - 3206

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 11

ER -